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Abstract
Background: Human serum albumin (HSA) is the most abundant protein in blood plasma, having high affinity binding sites
for several endogenous and exogenous compounds. Trimethoxy flavone (TMF) is a naturally occurring flavone isolated from
Andrographis viscosula and used in the treatment of dyspepsia, influenza, malaria, respiratory functions and as an astringent
and antidote for poisonous stings of some insects.
Methodology/Principal Findings: The main aim of the experiment was to examine the interaction between TMF and HSA at
physiological conditions. Upon addition of TMF to HSA, the fluorescence emission was quenched and the binding constant
of TMF with HSA was found to be KTMF=1.060.01610
3 M
21, which corresponds to 25.4 kcal M
21 of free energy. Micro-TOF
Q mass spectrometry results showed a mass increase of from 66,513 Da (free HSA) to 66,823 Da (HAS +Drug), indicating the
strong binding of TMF with HSA resulting in decrease of fluorescence. The HSA conformation was altered upon binding of
TMF to HSA with decrease in a-helix and an increase in b-sheets and random coils suggesting partial unfolding of protein
secondary structure. Molecular docking experiments found that TMF binds strongly with HSA at IIIA domain of hydrophobic
pocket with hydrogen bond and hydrophobic interactions. Among which two hydrogen bonds are formed between O (19)
of TMF to Arg 410, Tyr 411 and another one from O (7) of TMF to Asn 391, with bond distance of 2.1 A ˚, 3.6 A ˚ and 2.6 A ˚,
respectively.
Conclusions/Significance: In view of the evidence presented, it is imperative to assign a greater role of HSA’s as a carrier
molecule for many drugs to understand the interactions of HSA with TMF will be pivotal in the design of new TMF-inspired
drugs.
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Introduction
Flavonoids are naturally occurring polyphenolic compounds
used as food supplements which has anti-allergic, anti-inflamma-
tory, anti-microbial and anti-cancer activity. Dietary flavonoids
can be detected in plasma as serum albumin-bound conjugates and
are receiving increasing attention as potential prophylactics against
a variety of human diseases, in particular cardiovascular disease
and cancer [1–3]. A large number of mechanisms of action have
been attributed to flavonoids, including antioxidant properties [4–
7] and effects on enzymes and signal transduction pathways. The
anti-oxidative protections are related to their binding modes to
DNA duplex and complexation with free radicals in vivo. However,
flavonoids are known to inhibit the activities of several enzymes
such as calcium phospholipid-dependent protein kinase, tyrosine
protein kinase from rat lung, phosphorylase kinase and DNA
topoisomerases; these cases emphasize the additional importance
of flavonoid-protein interactions [8–10].
Flavonoids display moderate affinities for albumins with binding
constants in the range of 1–15610
4 M
21 [11]. Also, it is known
that flavones and flavonols bind very tightly to albumin. Flavones
are a class of flavonoids based on the backbone of 2-phenyl-1-
benzopyran-4-one. Flavones which are used in anti-depression
treatment are known to inhibit human cytochrome P450 (CYP)
enzyme activities [12]. Hydrophobicity, the presence/absence of
some functional groups, steric hindrance and spatial arrangement
all play important roles in the affinity of natural polyphenols
towards plasmatic proteins [13].
Tri-methoxy flavone (TMF) is a naturally-occurring compound
present in Andrographis viscosula. This plant has been used in
Ayurvedic medicine to cure many diseases. The plant’s extract
exhibits antityphoid and antifungal activities. This extract also
reported to possess antihepatotoxic, anti-HIV, antibiotic, antima-
larial, antihepatitic, antithrombogenic, antiinflammatory, anti-
snake venom, and antipyretic properties to mention a few, besides
its general use as an immuno-stimulant agent. Various species of
Andrographis are used in the treatment of dyspepsia, influenza,
malaria and respiratory functions and as a astringent and antidote
for poisonous stings of some insects [14–16]. Although TMF has
several clinical applications, however, its molecular interaction
with human serum albumin has not been reported.
Human serum albumin is a major extracellular protein with
high affinity for a wide range of metabolites and drugs [17–25]
and its abundance is high in the blood plasma (40 mg ml
21)
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to bring such solutes into the bloodstream and deliver them to the
target organs and to maintain the pH. In addition to its ordinary
clinical applications such as hypovolemic shock treatment, many
investigators have attempted to utilize HSA as carrier to deliver
various drugs to their specific target organs. HSA is a single non-
glycosylated, 67 kDa polypeptide, which folds into a heart shaped
protein with approximately 67% a-helical content [28–34]. It is a
globular protein composed of three structurally similar domains
(I–III), each consisting of two subdomains (A and B) and stabilized
by 17 disulfide bridges. The two primary binding sites (site I and
site II) are hydrophobic cavities located in subdomains IIA and
IIIA, respectively. Most compounds binds to these two sites with
an affinity constant of 10
4 to 10
6 M
21 [28,34,35]. In addition,
seven binding sites for fatty acids are localized in sub-domains IB,
IIIA and IIIB, and on the sub-domain interfaces [27,32,36]. HSA
also has a high-affinity metal binding site at the N-terminus [27].
There are many reports containing studies on HSA structure and
its interactions with different ligands [18–24]. Very recent reports
from our group [37,38] show that the natural products of
pentacyclic triterpenoids, betulinic acid and feruloyl maslinic acid
isolated from Tephrosia calophylla and Tetracera asiatica form strongly-
bound ligand–HSA complexes. Interactions with plasma proteins,
especially HSA, are important factors to be considered in drug
development. The interactions of TMF with HSA are significant
for understanding its transport and distribution and to clarify its
action mechanism and pharmaceutical dynamics.
In this study, the interactions of TMF with HSA was
investigated by using fluorescence emission, circular dichroism
(CD), micro-TOF Q mass spectrometry and molecular docking
studies.
Materials and Methods
Isolation and Purification of TMF
The whole plant of A. viscosula (2.5 Kg) was shade dried,
powdered, and extracted with n-hexane (5133), Me2CO(5133),
and MeOH(5133), successively. The n-hexane (30 g) was purified by
column chromatography over silica gel, and eluted with a step
gradient of n-hexane and EtOAc. The eluates at n-hexane:EtOAc
ratios of 8:2, 7:3, and 1:1 were purified individually by repeated
silica gel chromatography followed by preparative TLC (developed
with benzene/EtOAc, 9:1) to yield 10 mg of tri-methoxy flavones
[16]. The
13C NMR spectrum shows that the structure of this
fraction was established as 5, 7, 29-trimethoxyflavone [16]. The
molecular mass is 312.31 Da and its molecular formula is C18H16O5
(Figure 1).
Preparation of Stock Solutions
Fat free human serum albumin (a kind gift from Virchow
biotech Pvt Ltd, Hyderabad) was dissolved in physiological
aqueous solution of 0.1 M phosphate buffer pH 7.2 to the final
concentration of 1.5 mM protein according to the previous
procedure [37]. It was observed that HSA is pure without any
contamination. Fluorescent tri-methoxyflavone was prepared
(2 mM) in 20:80 ethanol: water mixture. From our previous work,
a solution containing 20% ethanol has no effect [37,38], on HSA
secondary structure. The optimum physiological pH for HSA was
set to 7.2 as it has the maximum absorption at this pH [37], thus,
for all the experiments, we have used 0.1 M phosphate at pH 7.2
as a physiological buffer. The maximum binding time taken by the
TMF to HSA was also examined via absorption, fluorescence, CD
spectra, from the data it was found to be 10 min is the maximum
binding time taken, hence we used 10 minutes incubation for all
the experiments. All other chemicals are analytical grade
purchased from Sigma Aldrich.
Fluorescence Spectroscopy
The fluorescence emission spectra were recorded on a Jobin-
Yvon, FluoroMax-3 in a 1 cm quartz cell using excitation
wavelength of 285 nm. The excitation and emission slit widths
are 5 nm and 5 nm, respectively. The emission spectra were
recorded from 300 to 550 nm. The final concentrations of the
TMF used for absorption spectra were 0.005, 0.01, 0.02, 0.03,
0.04, 0.05, 0.06, 0.07 and 0.08 mM in 10 mM phosphate buffer
pH 7.2, and with a fixed HSA concentration 0.025 mM. TMF has
fluorescence in the range of 451 nm. However the fluorescence of
TMF has been subtracted from the HSA-TMF spectra.
Electrospray Ionisation Mass Spectrometry (microTOF-Q)
Positive ion mode mass spectra were recorded on a micro-TOF
Q (Bruker Daltonics, Bremen, Germany) equipped with an
electrospray ionization source. For these measurements, the
HSA concentration used was 0.15 mM and the TMF concentra-
tion was 0.2 mM. Free HSA and HSA–TMF were prepared in
5 mM ammonium acetate (pH 7.2) mixed with 20% acetonitrile,
and introduced into the mass spectrometer source with a syringe
pump (KD Scientifics Inc., Hilliston, MA) at 3 mL/min. Electro-
spray was performed by setting the spray voltage at 4.5 kV. The
Time-of-Flight (TOF) pressure was maintained at less than
3610
27 Torr. Scanning was performed over an m/z range of
50–3000, with collision energy of 10 eV. Data were averaged for
2 min and then smoothed using the Gaussian algorithm in the
Bruker data analysis 3.4 software program. The instrument was
calibrated using ES Tuning Mix (Agilent Technologies, part
No. G2421-60001), diluted 1:60 (v/v) times with 95% acetonitrile
and injected through a divert valve just before sample application.
Circular Dichorism Spectroscopy
Circular dichroism (CD) spectra of HSA and HSA–TMF were
recorded with a Jasco J-810 spectropolarimeter, using a quartz cell
with a path length of 0.02 cm. Five scans were accumulated at a
scan speed of 50 nm min
21, with data being collected at every
1 nm from 190 to 300 nm. An ellipticity of CD spectra is
expressed in millidegrees. The protein secondary structure was
calculated using CDNN 2.1 software. For CD studies, the final
Figure 1. Chemical structure of Tri-methoxy flavone. The
molecular mass is 312.31 Da and its molecular formula is C18H16O5.
doi:10.1371/journal.pone.0008834.g001
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at TMF concentrations of 0.01, 0.025 and 0.08 mM. Tempera-
tures of samples were maintained by Jasco J-715 peltier.
Molecular Modeling and Docking
Genetic algorithm. GOLD (Genetic Optimization for
Ligand Docking), a docking program based on genetic algorithm
[39–42] was used to dock the ligands to the protein active sites.
Genetic algorithm is a computer program that mimics the process
of evolution by structures called chromosomes. Each of these
encodes a possible solution (in terms of a possible ligand-receptor
interaction) to the docking problem and may be assigned fitness
score based on the relative merit of that solution. Each
chromosome encodes an internal conformation and protein
active site, and includes a mapping from hydrogen bonding sites
in the ligand and protein. On decoding a chromosome, least-
squares fitting process is employed to position the ligand within the
active site of the protein. The fitness of a decoded chromosome is
then a combination of the number and strength of the hydrogen
bonds that have been formed in this way and of the vander Waals
energy of the bound complex.
Preparation of the protein and the ligand. A crystal
structure of HSA (PDB ID: 1AO6) was obtained from the
Brookhaven Protein Data Bank. A three dimensional structure of
TMF was built and the geometry optimized using the discover3
feature in the InsightII/Builder software package. Water molecules
and ions were removed (including ordered water molecules) and
hydrogen atoms added at appropriate geometry; groups within the
protein were ionized as required at physiological pH. The structure
of HSA was protonated in InsightII (www.accelrys.com). The
genetic algorithm implemented in GOLDv3.2 was applied to
calculate the possible binding conformations of the drug.
Genetic algorithm parameters used. The parameters used
for genetic algorithm were active site radius-30; Population size-
100; Number of Islands-5; Niche size-2; Selection pressure-1.1;
Migrate-10; Number of operators-100,000; Mutate-95; Crossover-
95. The default speed selection was used to avoid a potential
reduction in docking accuracy. Fifty genetic algorithm runs with
default parameter settings were performed without early
termination. To estimate the protein-ligand complexes, scoring
function, GOLD score was employed [41].
During docking process a maximum of 10 different conforma-
tions were considered for the TMF. Among which the best and the
most three energetically favourable conformations with fairly
similar GOLD fitness score of each ligand was selected. The
conformer with the lowest binding free energy with highest fitness
score was used for further analysis [41,43].
Results and Discussion
Fluorescence Spectroscopy
Fluorescence emission spectroscopy was used to find the drug-
protein interactions and measure binding affinity [44]. The
emission fluorescence of HSA comes from tryptophan, tyrosine,
and phenylalanine. Phenylalanine has a very low quantum yield
and the fluorescence of tyrosine is almost totally quenched if it is
ionized or present near to an amino group, a carboxyl group or a
tryptophan. Thus, the fluorescence of HSA is dominated by the
tryptophan emission, and the emission spectrum of HSA is mainly
from a single residue Trp-214 in subdomain IIA. A change in the
intrinsic fluorescence intensity of HSA was due to the tryptophan
residue when small molecules bound to HSA [45].
Figure. 2A shows the fluorescence emission of HSA is obtained
at 362 nm. Different concentrations of TMF were used to study
the interaction with HSA. Our results showed that, with increasing
concentrations of TMF (0.005 to 0.08 mM) and a fixed
concentration of HSA (0.025 mM), the maximum fluorescence
(362 nm) of HSA was quenched upon binding of TMF
(Figure. 2A). This indicates that TMF binding to HSA causes
microenvironment changes in HSA and leads to HSA-TMF
complexes. TMF also shows fluorescence emission at 451 nm (see
Figure. 2A). Similar fluorescence quenching results were reported
for several ligands [46,47].
The binding constant can be calculated from the modified
Stern-Volmer plot according to the following equation [48]
Log F0{F ðÞ ðÞ ðÞ ðÞ ðÞ ðÞ ðÞ ðÞ ðÞ ðÞ =F ½  ~ log KSz n   log Q ðÞ ðÞ ðÞ ðÞ ðÞ ðÞ ðÞ ðÞ ðÞ ðÞ ð 1Þ
where n is the slope (i.e. the number of binding sites), KS is the
binding constant and Q is the quencher concentration. The result
indicated a good linear relationship (see Figure. 2B), suggesting
that HSA interacts with TMF in a one-to-one ratio. The binding
constant KTMF was calculated from the intercept as
1.060.01610
3 M
21, which indicates an adequate binding of
TMF to the protein. The calculated binding constants show a
comparatively weak ligand-protein interaction, corresponds to
other strong ligand-protein complexes like monoclonal antibodies
with binding constants from 10
7 M
21 to 10
10 M
21 [49]. It is
important to note that natural products showed binding constants
which are in the order of magnitude smaller than 10
7 M
21 to
10
10 M
21. Other flavonoids like, quercitin binds with an affinity of
Figure 2. Fluorescence emission spectra of HSA–TMF in 0.1 M
phosphate buffer pH 7.2, lex=285 nm, temperature=2561uC.
A) Free HSA (0.025 mM) and free HSA with different concentrations of
TMF (0.005, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08 mM). B) Plot of log
(dF/F) against log [Q]. lex=285 nm lem=362 nm.
doi:10.1371/journal.pone.0008834.g002
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4 M
21 [50] and resveratrol a polyphenol binds with an
affinity of 1.64610
5 M
21 [51].
The standard free energy change can be calculated according
to:
DG
0~{ RT ln K ð2Þ
where DG is the free energy, K is the binding constant at the
corresponding temperature (which can be obtained from fluores-
cence data as described above) and R is the gas constant. Thus, the
standard free energy change is calculated to be 25.4 kcal/mol at
25uC upon binding of TMF to HSA. This indicates that the free
energy of binding for the TMF–HSA complex derives mainly from
hydrophobic and possibly hydrogen bond interactions. Our data is
Figure 3. Micro TOF-Q mass spectra. A) free HSA, and B) HSA along with TMF. The concentration of free HSA and TMF were 0.15 mM and 0.2 mM,
respectively.
doi:10.1371/journal.pone.0008834.g003
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silibinin and genistein to HSA [21,52].
Micro TOF-Q Analysis
Mass spectrometry is often used in pharmacokinetic studies due
to its high sensitivity in detecting compounds at low concentra-
tions. Protein–ligand complexation at micro molar levels was
demonstrated here using micro TOF-Q mass spectrometry. The
mass spectra of free HSA and HSA-TMF complexes can be
observed in Figure 3A & 3B. The numbers on dark vertical lines
indicate the matched charge states of HSA and HSA-TMF
complexes. Deconvolution of the multiple charged states resulted
in the mass determinations of HSA and HSA-TMF complexes.
When analyzing the HSA-TMF sample a molecular mass increase
from 66513 Da to 66823 Da was observed, indicating that TMF
was bound to HSA. As the molecular weight of TMF is 312 Da
the additional mass of 310 Da indicated that the interaction of
TMF to HSA is 1:1. These results are in agreement with the above
fluorescence data. Our group recently illustrated the betulinic acid
and feruloyl maslinic acid bound to the HSA in 1:1 and 1:2
showed by micro TOF-Q mass spectrometry [37,38].
CD Spectroscopy Studies
In general the CD spectroscopy used to study the secondary
structure of proteins and their conformational changes. The CD
spectra of HSA exhibits two negative bands in the ultraviolet
region at 208 and 218 nm as shown in Figure 4. The secondary
structure was determined using CDNN 2.1, software for protein
secondary structure analysis. The secondary protein conformation
found to be 57.3% a-helix, 24.9% b-sheet (including parallel and
anti-parallel) and 17.8% random coil, respectively, which is in
close agreement with our previous reports [37,38]. By this method
it was found that upon complexation of HSA with TMF (0.01,
0.025, 0.08 mM), the a-helical content of the protein decreased
from 57.3% to 47% with a increase in b-sheets from 24.9% to
31.5%, and random coils 17.8% to 22%, respectively (Table 1).
Our results suggest that the changes in the secondary structural
components arise from partial unfolding of HSA upon binding of
TMF. Several previous reports also indicate that conformational
changes occur in HSA due to complexation with ligands [11,36–
38,51,53–55]. In our experiment, the near UV-CD shows that
there is no modification in the tertiary structure upon complex-
ation of TMF (data not shown). Thus, the protein conformation in
our experiments arises due to change in the local structural
changes in secondary structural components.
In order to determine the stability of HSA-TMF complexes,
temperature-dependent CD was carried out for HSA alone
(0.025 mM) (Figure 5A) and HSA with 0.08 mM TMF
(Figure 5B), from 25–85uC. The secondary structural conformation
of protein is not significantly changed up to 60uCi nb o t hf r e eH S A
alone and HAS+TMF complexes (Figure 5C). Above 65uC, the a-
helical content decreased dramatically, while the b-sheet and
random coil content increased in both HSA and HSA-TMF
complexes. It is interesting to observe that HSA alone exhibits
conformational changes from 65uC (Figure 5A). The previous report
shows that the Tm of the HSA alone was around 65uC, which shows
that the unfolding of protein occurs only after this point [56]. The
secondary structural conformation was noticed in free HSA and
TMF+HSA complexation (0.08 mM) that the a-helical contents
were 57.3% and 47%, b-sheets 24.9% and 31.5%, and random coils
17.8% and 22%, respectively. The temperature dependent CD
conformational changes remained same in both free HSA and
HSA+TMF complexes, which indicate that there is no release of
TMF from its complexation. These results indicate that the HSA-
TMF complexes were not affected by temperature upto 60uCa n d
thus, HSA-TMF complexes were conformationally and thermody-
namically stable upto 60uC. Further, the protein conformation is
dramatically decreased due to thermal denaturation.
Molecular Docking
Computational molecular docking has been employed to
improve the understanding of the interaction of TMF and HSA.
As described above, the 3D crystal structure of HSA is a monomer
consisting of three homologous domains which assemble to form a
heart shaped molecule. Each of the structurally similar a-helical
domains (I–III) has two subdomains (A and B), with six a-helices in
subdomain A and four a-helices in subdomain B. The fluorescent
tryptophan residue 214 is in subdomain IIA [28]. Several studies
have shown that HSA is able to bind many ligands in several
binding sites [34]. In the present study, the GOLD v3.2, was
chosen to examine the binding mode of TMF at active site of
HSA. The figure 6 shows the location of tryptophan and also the
binding of TMF (Figure 6A & 6B).
The outer surface of the IIA and IIIA subdomains exhibits
several hydrophobic pockets [20] and most ligands bind to this
region. The present study indicates that TMF binds within the
hydrophobic pocket of subdomain IIIA (see Figure 6C). The side
chain of Arg410 is located at the mouth of the pocket while the
hydroxyl group of Tyr411 faces toward the inside of the pocket.
The complexation of HSA-TMF is stabilised primarily by three
hydrogen-bond interactions. The hydrogen bonds are formed with
Figure 4. Circular dichroism of the free HSA and HSA+TMF
complexes. The free HSA and HSA+TMF complexes in aqueous
solution with a protein concentration of 0.025 mM and TMF
concentrations were 0.01, 0.025 and 0.08 mM.
doi:10.1371/journal.pone.0008834.g004
Table 1. Secondary structural analysis of the free HSA and its
interaction with TMF.
HSA
HSA-0.025
mM TMF
HSA-0.05
mM TMF
HSA-0.08
mM TMF
a–Helix (%) 57.362.5 51.162.25 48.162.0 4762.0
Anti-parallel (%) 6.0560.4 6.8960.4 7.160.4 7.160.4
Parallel (%) 6.6560.4 6.960.3 7.260.5 7.460.4
b–Sheet (%) 12.260.8 14.460.75 16.861.0 1761.0
Random coil (%) 17.861.8 20.7161.2 21.461.2 2262.0
Based on the Figure 4, the data analyzed by web based software CDNN 2.1.
doi:10.1371/journal.pone.0008834.t001
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2.6 A ˚, another two H-bonds between O(19) of TMF and Arg410,
Tyr411 with bond distances of 2.1 A ˚, 3.6 A ˚ respectively (see
Figure 6B & 6C). The fluorescence quenching occurred due to
Trp-214 in IIA domain, that any perturbation in Trp-214 in
subdomain IIA may induce changes in IIIA domain as well [57].
The results suggest that the formation of new hydrogen bonds
decreased the overall hydrophilicity and increased the hydropho-
Figure 5. Temperature-dependent CD-Spectra of free HSA and HSA+TMF complexes. A) HSA alone and B) CD spectra of HSA+0.08 mM
TMF complexes. C) Secondary structure composition calculated from Figure 5A, HSA alone and Figure 5B, HSA-TMF complexes with temperature
dependent. The temperature dependance for both free HSA and HAS+TMF complexes from 25 to 85 with an interval of 10uC.
doi:10.1371/journal.pone.0008834.g005
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PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8834Figure 6. Molecular docking of HSA with TMF. A) Schematic representation of HSA molecule. Each subdomain is marked with a different colour
(Red for subdomain IA; yellow, IIA; purple IIIA; blue, IIB; orange, IB; green, IIIB) Asn391, Arg410 and Tyr411 involved in Binding of TMF, Trp-214 are
coloured white. B) Graphical representation of HSA-TMF complex (prepared by using SILVERv1.1.1 visualizer), TMF Complex represented as capped sticks,
and the residues as ellipsoid model. Three H-bonds (as highlighted by the dashed lines in green colour) were formed between TMF and HSA. The
hydrogen bond lengths were represented in green colour. C) Graphical representation of HSA showing TMF docked in the binding pocket of HSA using
GOLDv3.2.TMF, depicted in stick model (light green), and HSA, represented in solid (better) with ray model. The image was visualised by using PyMol.
doi:10.1371/journal.pone.0008834.g006
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computationally calculated free energy change DG
0 for TMF-
HSA binding is 26.1 kcal.mol
21, and the binding constant is
KTMF 1.2610
3 M
21. These results are very close to the
experimentally-measured values of DG
0=25.4 kcal/mol and
KTMF=1.060.01610
3 M
21. Therefore, the molecular docking
and free energy calculation results suggested that TMF bound to
HSA with both hydrophobic and hydrogen bond interactions.
In conclusion, TMF from Andrographis viscosula Nees binds to
HSA with an affinity of KTMF=1.060.01610
3 M
21 and a
binding free energy of 25.4 kcal M
21 at 25uC. Circular dichroism
results indicate partial unfolding of the protein upon TMF binding
and also indicated that these complexes are conformationally and
thermodynamically stable. Mass spectrometry data reveals the
additional mass increase is due to 1:1 interaction of HSA to TMF.
Further, molecular docking studies concluded that TMF-HSA
complex is stabilised by three hydrogen bonds: one between the
O(7) of the TMF and Asn391 with a bond length of 2.6 A ˚ and two
H-bonds between O(19) of TMF and Arg410 and Tyr411 with
bond distances of 2.1 A ˚ and 3.6 A ˚ respectively. Nonetheless, the
TMF was bound to HSA mainly by hydrogen and hydrophobic
interactions. The biological importance of this study lies in HSA’s
role as a carrier molecule for many drugs–understanding the
interactions of HSA with TMF will be essential in the design of
new TMF-inspired drugs. This approach to drug development
based on natural products and traditional medicine could be a
major development in the pharmaceutical industry, chemistry, life
sciences and clinical medicine.
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